Vixen Pharmaceuticals - Ownership and Business Overview

Life ScienceCompany

Vixen Pharmaceuticals Ownership

Who owns Vixen Pharmaceuticals?

Vixen Pharmaceuticals is owned by Aclaris Therapeutics. It was acquired on March 28, 2016.

Vixen Pharmaceuticals Business Overview

Where is Vixen Pharmaceuticals headquartered?

Vixen Pharmaceuticals is headquartered in United States.

What sector is Vixen Pharmaceuticals in?

Vixen Pharmaceuticals is a life science company.

Life Science M&A Summary in 2016

Out of 60 sectors in the Mergr database, life science ranked 8 in number of deals in 2016. The largest life science acquisition in 2016 was Baxalta - which was acquired by Shire for $32.0B.

Join Mergr to view all 293 acquisitions of life science companies in 2016, including 32 acquisitions by private equity firms, and 261 by strategics.

Vixen Pharmaceuticals, Inc.


United States,

Vixen Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company.


 Subscribe to unlock this and 206,153
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 198K M&A Transactions
  • 202K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 80K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.

Related Lists for Vixen Pharmaceuticals

Life Science Companies , United States Companies